It can serve as an alternative delivery method, but it is not a direct replacement
Those with obesity-related comorbidities such as obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, or polycystic ovary syndrome may experience improvements in these conditions as a result of significant weight reduction, though these are not FDA-approved indications for semaglutide
7 Beyond weight loss Semaglutide has gained significant attention for its positive effects in managing type 2 diabetes (T2D), obesity, and cardiovascular risk reduction
Semaglutide is a medication in the GLP-1 receptor agonist class
Delays Gastric Emptying: Significantly slows the rate at which gastric contents empty into the duodenum, allowing food to remain in the stomach for a longer period
Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment